Methylnaltrexone bromide - Progenics Pharmaceuticals/Valeant Pharmaceuticals

Drug Profile

Methylnaltrexone bromide - Progenics Pharmaceuticals/Valeant Pharmaceuticals

Alternative Names: Methyl-naltrexone hydrobromide; Methylnaltrexonium; MNTX; MNTX 302; MOA-728; MRZ 2663BR; MRZ-2663; N-methylnaltrexone bromide; Naltrexone MB; Naltrexone methobromide; Naltrexone methylbromide; Naltrexonium methiodide; ONO-3849; Quaternary ammonium naltrexone; Relistor; Relistor Oral

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Chicago
  • Developer Glycyx Pharma Ventures; Ono Pharmaceutical; Progenics Pharmaceuticals; Salix Pharmaceuticals
  • Class Morphine derivatives; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Marketed Constipation
  • Research Pancreatic cancer
  • Discontinued Postoperative ileus; Urination disorders

Most Recent Events

  • 15 Mar 2017 Glycyx PharmaVentures and Valeant Pharmaceuticals enter into a license agreement for Oncology indications
  • 15 Mar 2017 Early research in Cancer in Isle of Man
  • 09 Mar 2017 Valeant Pharmaceuticals has patent protection for methylnaltrexone bromide in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top